WPSS.bio

Zachary Weinberg and Nat Turner serve as the firm's managing partners and are the sole disclosed investment decision-makers. Both were co-founders of Flatiron Health, the oncology data platform Roche acquired for $1.9 billion in 2018. No additional investment committee members or external advisors have been publicly identified, consistent with a tight operator-investor structure.

The firm sources primarily through the clinical-data networks and pharma sponsor relationships established during the Flatiron Health era. Weinberg and Turner retain deep ties to oncology research sites, regulatory-data consultancies, and digital-pathology vendors — channels that surface startups building infrastructure for clinical trials and real-world evidence generation. This network-based sourcing model gives the firm early visibility into healthtech companies before they reach formal institutional fundraising rounds.

WPSS.bio operates as a private investment vehicle funded by the founders' Flatiron Health exit proceeds, without disclosed outside limited partners — making it structurally closer to a single-family office or holding company than a traditional venture capital fund. It does not publicly report fund sizes, fee structures, or institutional LP commitments, and appears to invest on a deal-by-deal basis rather than through a blind pool.

The firm concentrates on seed and early-stage start-up rounds, occasionally participating in Series A financings. Its public record of investments skews toward companies still building regulatory-grade data infrastructure and clinical-validation pipelines, where early entry aligns with the founders' ability to diligence complex health-data workflows.

The primary investment geography is the United States, though the firm has shown awareness of European clinical-trial data infrastructure opportunities — a natural extension of the multinational trial networks Flatiron Health served. No dedicated non-US office or regional fund vehicle has been publicly disclosed.

WPSS.bio is a separate entity with no publicly disclosed operational or capital relationship with Flatiron Health or Roche. The connection is historical and reputational: Weinberg and Turner built Flatiron into a dominant oncology data platform before Roche's acquisition, and their investment thesis at WPSS.bio draws on the same clinical-data infrastructure expertise.

Yes, public deal announcements show WPSS.bio co-investing alongside specialist healthtech venture funds. The firm appears to welcome syndicate participation, particularly where co-investors bring complementary clinical-trial or regulatory expertise rather than just balance-sheet capital.